MITRA-HR: The design and rationale of a randomised study of MitraClip transcatheter mitral valve repair in patients with severe primary mitral regurgitation eligible for high-risk surgery
Source: View publication →
The MITRA-HR trial is a prospective, randomized, multicenter study designed to assess whether transcatheter edge-to-edge repair (TEER) with the MitraClip system is non-inferior to conventional surgical mitral valve repair in high-surgical-risk patients with severe primary mitral regurgitation.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial addresses the unmet need for a safer, less invasive alternative to open-heart surgery for patients with degenerative (primary) mitral regurgitation who are considered at high surgical risk, potentially shifting the standard of care if non-inferiority is confirmed.
Historical Context
Following the success of the MitraClip in the EVEREST II trial and the subsequent debate regarding its application in secondary (functional) mitral regurgitation (as seen in COAPT and MITRA-FR), interest has grown in evaluating its role specifically in primary degenerative disease for high-risk cohorts where surgical morbidity remains a significant clinical concern.
Guided Discussion
High-yield insights from every perspective
What is the fundamental pathophysiological difference between primary and secondary mitral regurgitation, and why does this distinction matter when assessing the efficacy of the MitraClip system?
Key Response
Primary MR is a degenerative disease of the valve apparatus itself (e.g., flail leaflet, prolapse), whereas secondary MR is a disease of the left ventricle (e.g., dilation leading to tethering). In primary MR, the goal is definitive structural repair. The MitraClip's efficacy in primary MR must be compared against the high success rate of surgical repair, which is the gold standard for restoring normal anatomy and life expectancy.
When managing a patient with symptomatic severe primary mitral regurgitation, how do current risk scores (like STS or EuroSCORE II) and the 'Heart Team' concept influence the selection between TEER and conventional surgery in the context of the MITRA-HR trial design?
Key Response
The MITRA-HR trial specifically targets patients at 'high surgical risk.' Residents must understand that risk is not just a number (e.g., STS >8%) but also includes 'porcelain' aorta, frailty, and chest radiation. The Heart Team integrates these clinical realities to determine if the lower procedural morbidity of TEER outweighs the potentially superior long-term durability of surgical repair.
Given the findings of the EVEREST II trial, which showed surgery was superior to TEER for MR reduction in primary MR, how does MITRA-HR's inclusion of a high-risk cohort specifically address the limitations of prior evidence for transcatheter edge-to-edge repair?
Key Response
EVEREST II studied a lower-risk population where the 'cost' of surgical complications was low, making the durability of surgery a clear winner. MITRA-HR focuses on high-risk patients where the periprocedural 'hit' of surgery is significant. Fellows must interpret if avoiding surgical morbidity justifies the higher likelihood of residual MR (grade 2+) often seen with TEER in primary pathology.
If MITRA-HR proves non-inferiority for clinical outcomes, how will you reconcile the trade-off between procedural safety and the long-term risk of heart failure re-hospitalization driven by less-than-perfect MR reduction in your elderly but high-risk primary MR patients?
Key Response
This question addresses the 'real-world' dilemma: surgery offers a 'cure' but with high upfront risk; TEER offers a 'palliation' with low risk. Attendings must decide if a 75-year-old with primary MR and an STS of 8% is better served by a definitive 15-year surgical repair or a 'good enough' TEER result that may require more intensive medical management of residual MR over time.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MITRA-HR trial uses a composite primary endpoint of all-cause mortality, stroke, and unplanned CV hospitalization. Critically evaluate the use of a non-inferiority margin in this study: how does the expected high event rate in a high-risk population affect the statistical power and the risk of a Type II error in asserting equivalence?
Key Response
In high-risk populations, the baseline event rate is high. If the non-inferiority margin is too wide, the trial may fail to exclude clinically important differences. Conversely, if the margin is tight but the sample size is limited, the study may be underpowered to prove non-inferiority even if the treatments are truly similar. This requires a rigorous calibration of the 'Delta' (margin) based on historical surgical data.
As a reviewer, if the MITRA-HR data shows non-inferiority in the composite clinical endpoint but a statistically significant difference in residual MR (MitraClip > Surgery), would you advocate for a 'neutral' or a 'negative' conclusion regarding the utility of TEER in primary MR?
Key Response
Editors look for 'clinical significance' versus 'statistical non-inferiority.' Residual MR is a surrogate for long-term LV remodeling and late failure. A tough reviewer would argue that if the trial is only 1-2 years long, a non-inferior clinical result is misleading because the 'penalty' for residual MR in the TEER arm might only manifest 5 years later, which is critical in primary (degenerative) disease.
Current AHA/ACC guidelines provide a Class 2a recommendation for TEER in primary MR for patients with high surgical risk. How would the MITRA-HR results need to differ from COAPT (which focused on secondary MR) to justify upgrading TEER to a Class 1 recommendation for primary MR?
Key Response
To achieve a Class 1 recommendation (Level A evidence), MITRA-HR would need to demonstrate not just safety non-inferiority, but comparable long-term survival and quality of life to surgery. Unlike COAPT, where TEER was compared to medical therapy for a ventricular problem, MITRA-HR compares it to the definitive surgical gold standard. Guidelines currently favor surgery for primary MR because it effectively 'cures' the valve; TEER would need to prove its durability is 'good enough' to avoid the late attrition seen in early TEER trials.
Clinical Landscape
Noteworthy Related Trials
EVEREST II Trial
Tested
MitraClip system
Population
Patients with moderate-to-severe or severe mitral regurgitation
Comparator
Mitral valve surgical repair or replacement
Endpoint
Composite of death, major cardiovascular surgery, or reoperation for mitral valve dysfunction
COAPT Trial
Tested
MitraClip plus guideline-directed medical therapy
Population
Patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation
Comparator
Guideline-directed medical therapy alone
Endpoint
All hospitalizations for heart failure within 24 months
MITRA-FR Trial
Tested
MitraClip plus guideline-directed medical therapy
Population
Patients with severe secondary mitral regurgitation and heart failure
Comparator
Guideline-directed medical therapy alone
Endpoint
Composite of all-cause death or unplanned hospitalization for heart failure at 12 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis